Ani Pharmaceuticals (ANIP) EBIAT (2016 - 2025)
Historic EBIAT for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $26.6 million.
- Ani Pharmaceuticals' EBIAT rose 21014.23% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 67214.78%. This contributed to the annual value of -$18.5 million for FY2024, which is 19863.15% down from last year.
- Latest data reveals that Ani Pharmaceuticals reported EBIAT of $26.6 million as of Q3 2025, which was up 21014.23% from $8.5 million recorded in Q2 2025.
- In the past 5 years, Ani Pharmaceuticals' EBIAT ranged from a high of $26.6 million in Q3 2025 and a low of -$24.2 million during Q3 2024
- Over the past 5 years, Ani Pharmaceuticals' median EBIAT value was -$2.3 million (recorded in 2024), while the average stood at -$2.1 million.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 2350697.67% in 2022, then soared by 116525.36% in 2024.
- Quarter analysis of 5 years shows Ani Pharmaceuticals' EBIAT stood at -$24.1 million in 2021, then skyrocketed by 82.42% to -$4.2 million in 2022, then surged by 127.22% to $1.2 million in 2023, then plummeted by 989.7% to -$10.3 million in 2024, then soared by 359.02% to $26.6 million in 2025.
- Its last three reported values are $26.6 million in Q3 2025, $8.5 million for Q2 2025, and $15.7 million during Q1 2025.